Clinical Trials Browser

Recruiting × Everolimus × NET × Clear all

NCT05773274 2026-03-18

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Phase 2 Recruiting

100 enrolled

EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

NCT04665739 2026-03-17

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Phase 2 Recruiting

70 enrolled

EndocrineNET

Advanced Lung Neuroendocrine Tumor

NCT05918302 2026-03-06

LEVEL

Phase 3 Recruiting

120 enrolled

EndocrineNET

Thymus Neoplasms, Neuroendocrine Tumors

NCT06943755 2026-02-27

STELLAR-311

Phase 2/3 Recruiting

440 enrolled

EndocrineNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Phase 1 Recruiting

27 enrolled

EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT05477576 2026-01-20

ACTION-1

Phase 3 Recruiting

288 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT07165886 2025-09-10

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Phase 2/3 Recruiting

243 enrolled

EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT06472388 2024-06-25

EVENET

Phase 2 Recruiting

100 enrolled

EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression